Press release
Nasus Pharma Receives $22 Price Target and Buy Rating From Laidlaw & Company
A Closer Look at Nasus Pharma
Nasus Pharma is developing a dry powder intranasal delivery system aimed at transforming treatment in acute, life-threatening conditions where every minute matters.
The lead program, NS002, targets the $3 billion anaphylaxis treatment market by delivering epinephrine through a simple nasal spray rather than an auto-injector. Compliance with injectable devices has historically been low due to needle phobia, bulkiness, and user error in emergencies. Nasus's powder spray is designed to overcome those barriers, potentially improving both speed of administration and patient adherence. Early studies suggest that NS002 may deliver epinephrine more rapidly to therapeutic blood levels than current injection-based standards.
Nasus's approach is not limited to anaphylaxis. The same powder-based platform has already been applied to an intranasal naloxone product for opioid overdose reversal and to a COVID-19 antiviral spray, demonstrating versatility across therapeutic areas. This breadth creates multiple potential "shots on goal" for the company beyond its flagship allergy program.
The competitive landscape is also validating the concept. ARS Pharma's Neffy, a liquid-based nasal epinephrine spray, received FDA approval in 2024 and has quickly gained market share, showing that regulators and patients are receptive to needle-free delivery. Nasus's powder formulation may offer advantages in absorption speed, device usability, and stability compared to liquid sprays.
With a post-IPO market cap of around $75 million, Nasus is significantly smaller than peers already active in the space, yet it is targeting a large and growing global epinephrine market projected to reach $6-7 billion by 2030. Upcoming catalysts include further Phase 2 studies of NS002, progress on manufacturing scale-up, and eventual regulatory milestones as the company moves toward Phase 3 trials.
Recent News from Nasus Pharma: [https://www.globenewswire.com/news-release/2025/08/14/3133840/0/en/Nasus-Pharma-Announces-Closing-of-Initial-Public-Offering.html]
Disclaimer & Disclosure: This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Investing in small-cap and micro-cap securities is highly speculative and involves significant risk, including the potential loss of your entire investment. This content is a form of paid promotional content and advertising. Wall Street Wire receives cash compensation from Nasus Pharma Ltd for promotional media services provided on an ongoing subscription basis. The exact terms and amounts of this compensation, along with full disclosure information regarding the operator of Wall Street Wire, are available at: http://wallstwire.ai/disclosures. References to analyst ratings, price targets, market size estimates, or other third-party data are provided strictly for informational purposes. Wall Street Wire does not endorse, confirm, or guarantee the accuracy of such information. This article should not be considered an official communication by the issuer.
Media Contact
Company Name: Wall Street Wire
Contact Person: Staff
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nasus-pharma-receives-22-price-target-and-buy-rating-from-laidlaw-company]
Country: United States
Website: https://wallstwire.ai/disclosures
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Nasus Pharma Receives $22 Price Target and Buy Rating From Laidlaw & Company here
News-ID: 4202592 • Views: …
More Releases from ABNewswire
Red Teaming vs Penetration Testing: Understanding the Difference
Image: https://www.abnewswire.com/upload/2025/12/bc1e8a773c50dd0c9305d06207de098f.jpg
The topic of red teaming vs penetration testing often creates confusion among security teams, decision-makers and technical stakeholders. Both approaches aim to uncover weaknesses, yet they work in very different ways. Many organisations rely on one method thinking it covers the role of the other. This misunderstanding can lead to gaps in visibility, unclear expectations and misplaced confidence.
A clearer view of pentest vs red team helps organisations make better…
Suburban Solutions Moving Announces New West Chester, PA Location to Strengthen …
West Chester, PA - Suburban Solutions [https://suburbansolutions.com/], a highly trusted and fast-growing moving company serving the Greater Philadelphia and Washington, DC regions, is proud to announce the opening of its newest location at 1271 Upton Cir, West Chester, PA 19380. This expansion marks an important step in the company's ongoing mission to provide dependable and accessible relocation support to more communities across Pennsylvania.
With this new branch, Suburban Solutions Moving aims…
LSLONG Launches New Premium Custom Polo Shirt Collection with Full OEM & ODM Sup …
Shenzhen LSLONG Garments Co., Ltd., a global leader in apparel manufacturing, has officially unveiled its new Premium Custom Polo Shirt [https://www.lslt-shirt.com/polo-shirt-categories/] Collection, combining advanced fabrics, innovative designs, and end-to-end customization solutions. This launch underscores LSLONG's 25 years of experience delivering high-quality OEM and ODM apparel services to brands across more than 50 countries. The collection aims to empower brands with versatile, stylish, and performance-driven Polo shirts while providing comprehensive support…
Arteestry Creations Plus Brings Unique Customizable Designs to Over 50 Product C …
Arteestry Creations Plus offers creative custom designs across an extensive range of products from apparel to home goods to magnets, serving customers seeking personalized items for holidays, special occasions, and everyday use. The growing e-commerce brand combines artistic creativity with broad product versatility, featuring licensed collections from Disney, Pixar, Marvel, and Star Wars alongside original designs that can be applied across different product types upon customer request.
Arteestry Creations Plus has…
More Releases for Nasus
The Underdog Disruptor: Why Nasus Pharma Could Be the Sleeper Stock Ready to Sha …
The Bottom Line: Millions of Americans rely on EpiPen every single day. Nasus Pharma (NYSE:NSRX) is developing a simple powder-based nasal spray alternative that could change the game. The company just recently IPO'd and still under the radar, but their proven platform has the potential to open multiple multi-billion-dollar markets - making this a rare early chance to potentially invest before most of Wall Street catches on.
Most people have never…
Anaphylaxis Treatment Market Size in 7MM is expected to grow at a decent CAGR by …
DelveInsight's "Anaphylaxis Market Insights, Epidemiology, and Market Forecast- 2032" report delivers an in-depth understanding of the Anaphylaxis, historical and forecasted epidemiology as well as the Anaphylaxis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Unlock key insights into the Anaphylaxis Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Anaphylaxis Therapeutics Market Outlook- https://www.delveinsight.com/sample-request/anaphylaxis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways…
Opioid Overdose Treatment Market Size in 7MM is expected to grow at a decent CAG …
DelveInsight's "Opioid Overdose Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Opioid Overdose, historical and forecasted epidemiology as well as the Opioid Overdose market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover which therapies are expected to grab the Opioid Overdose Market Share @ Opioid Overdose Market Outlook- https://www.delveinsight.com/sample-request/opioid-overdose-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Opioid Overdose Market Report
• The increase…
Naloxone Spray Market Outlook 2024: Exclusive Report By The Business Research Co …
The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2418
The Business Research Company offers in-depth market insights through Naloxone Spray Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The naloxone spray market size has grown exponentially in recent years. It…
Anaphylaxis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapie …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 8+ key pharma and biotech companies are working on 8+ pipeline drugs in the Anaphylaxis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Anaphylaxis Pipeline Insight, 2023" report by DelveInsight…
Naloxone Spray Global Market Growth, Production, Size, Share and Applications Fo …
The Business Research Company's global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032
The Business Research Company's Naloxone Spray Global Market Report 2023 identifies the increase in the prevalence of opioid overdoses is contributing to the growth of the naloxone spray market. Opioids include medicines such as morphine, fentanyl are used for the treatment of pain.
The global naloxone spray market…
